The efficacy of nifedipine in the treatment ofhypertension was assessed in 15 patients whose hypertension continued while being treated with atenolol 100 mg and bendrofluazide 5 mg daily. Nifedipine was added in doses of 10, 20, and 30 mg three times daily in a placebo controlled, double blind trial. One patient was withdrawn from the trial because of severe postural hypotension with the highest dose. Erect and supine blood pressure in the remaining 14 patients were significantly reduced by all doses of nifedipine. The drug was well tolerated but plasma potassium fell by 0-3 mmol(mEq)/l during treatment (p <0 05).
Introduction
In most cases hypertension is adequately controlled by a beta blocker, diuretic, or a combination of these. A few patients, however (almost one tenth in one study), require a third drug. ' Unfortunately, many third line agents have serious side effects -for example, the lupus syndrome with hydralazine,' hirsutism and fluid retention with minoxidil,3 and diabetes with diazoxide4 -and there is a need for new safer drugs. Calcium antagonists such as nifedipine and verapamil have been widely used in the treatment of angina pectoris. As they relax arteriolar smooth muscle' they also reverse the main haemodynamic abnormality in essential hypertension.6 Nifedipine has been shown to lower blood pressure as effectively as beta blockers,7 but its use as sole antihypertensive treatment is limited by side effects. 8 Unlike verapamil, nifedipine does not cause significant adverse electrophysiological9 or negative inotropic effects on the heart'0 and may safely be combined with a beta receptor blocking agent.7 It might therefore be a useful third step antihypertensive agent, if used in combination with a beta adrenergic blocking drug and a diuretic, to minimise its commonest side effects, palpitation and fluid retention.
We conducted a placebo controlled, double blind trial of nifedipine in patients whose hypertension was not controlled by atenolol and bendrofluazide. to take atenolol and bendrofluazide throughout the study. Nifedipine was added in increasing doses of 10 mg, 20 mg, and 30 mg, each for two weeks three times daily. A two week period of placebo was allocated at random within the eight week study so that the trial was double blind.
Patients were examined on the 14th day of each treatment period, two hours after taking medication. Blood pressure was measured in the right arm after patients had rested supine for 10 minutes. An electronic ultrasonic sphygmomanometer (Roche Ateriosonde) was used and the mean of three readings recorded. The radial pulse was counted for one minute and these measurements were repeated after patients had been standing for three minutes. A blood sample was taken for biochemical analysis and a physical examination was performed. The volume of the left foot was estimated at each visit in seven patients, by measurement of water displaced from an overflow cylinder. Symptomatic side effects were recorded on a standardised questionnaire administered at the end of each treatment period.
Compliance was checked by tablet count and by tablet diaries which the patients completed daily.
All patients gave informed consent and the study protocol was approved by the ethics committee of the Royal Postgraduate Medical School. The statistical tests applied were the paired t test and linear regression analysis and all results are expressed as mean (standard deviation).
Results
Fourteen patients completed the study and their data are reported. One patient was withdrawn because of severe postural hypotension symptoms with nifedipine 90 mg daily.
The patients had moderate hypertension with combined diuretic and beta adrenergic blockade: mean supine blood pressure was 166/101 mmHg and mean erect blood pressure 156/102 mmHg. During treatment with placebo there was a small fall in blood pressure compared with that recorded at screening (11/6 mm Hg supine and 10/7 mm Hg erect). The fig 3) . Heart rate did not change significantly when nifedipine was added or when the patient was standing (fig 1) , probably because of effective beta receptor blockade by atenolol.
There was no change in random blood glucose concentration or in renal fimction after nifedipine but there was a small and significant reduction in plasma potassium concentration (table II) . Hypokalaemia occurred in 11 of the 14 patients taking nifedipine but was reversed during the placebo period.
The mean foot volume of seven patients increased from 1288 (182) ml with placebo to 1355 (175) ml with nifedipine 20 mg three times daily (p < 0 05) and 1372 (209) ml with 30 mg three times daily (p < 0 01), although their body weight was hardly altered. If you fear such a thing, mix emolients with them. Again, sometimes by using discussives, the humours offending (which physicians usually call the peccant humours) is driven to some more noble part of the body, or else it draws more than it discusseth; in such cases, concoct and attenuate the matter offending before you go about to discuss it. From hence may easily be gathered at what time of the disease discussive medicines are to be used, viz about the declining of the disease, although in diseases arising from heat of blood, we sometimes use them in the encrease and state of them. They are known by the same marks and tokens attenuating medicines are, viz by their burning and biting quality, they being very hot, and of thin parts, void of any biting quality, therefore they contract not the tongue in tasting of them. (Nicholas Culpeper (1616-54) The Complete Herbal, 1850.)
